Novel glucose-lowering drugs for non-alcoholic fatty liver disease

Table 3 Comparison of hemoglobin A1c change from baseline in different treatment groups

	Studies	Participants	WMD	95%CI		P value
HbA1c change
DPP-4 inhibitors	6	166/166	-0.42	-0.58	-0.25	< 0.0001
GLP-1 RAs	7	1210/809	-0.29	-0.85	0.26	0.30
SGLT2 inhibitors	5	146/135	-0.36	-0.80	0.08	0.11
HbA1c change (placebo-controlled studies only)
DPP-4 inhibitors	5	102/102	-0.38	-0.71	-0.05	0.02
GLP-1 RAs	3	1009/566	-0.88	-1.56	-0.19	0.01
SGLT2 inhibitors	1	21/21	-0.50	-0.84	-0.16	0.004

HbA1c: Hemoglobin A1c; WMD: Weighted mean difference; CI: Confidence interval; DPP-4: Dipeptidyl peptidase-4; GLP-1 RA: Glucagon-like peptide-1 receptor agonists; SGLT2: Sodium-glucose cotransporter 2.